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Sir,
Severe hemolytic disease of the fetus and newborn
(HDFN) not related to anti-D (anti-RH1) and requiring
intrauterine transfusion or postnatal exchange transfu-
sion are most commonly caused by anti-Kell (anti-K1)
and anti-c (anti-RH4) w6x. However, antibodies directed
against low incidence antigen (LIA), particularly those
resulting from MNS polymorphism can also lead to life
threatening complications w5, 7x. In some fetuses or new-
borns presenting with severe anemia, and more partic-
ularly in the presence of anti-Kell (anti-K1) antibodies,
suppression of erythropoiesis may be observed. Anemia
is associated with reduced reticulocytosis, less erythro-
blastosis and less severe hyperbilirubinemia when com-
pared with similar hemoglobin levels but related to anti-D
(anti-RH1) alloimmunization w9x. These observations have
been supported by in vitro analysis, showing that sera
containing anti-Kell as well as monoclonal anti-Kell anti-
bodies suppressed the growth of Kell-positive erythroid
progenitors w8x. Here, we report a case of severe hypo-
regenerative anemia, due to an anti-Vw (anti-MNS9), that
was not detected by routine screening of alloantibodies
during pregnancy.
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A male newborn from a 32-year-old Caucasian woman,
gravida 2 para 1 (1 abortion), without history of transfu-
sion, was delivered by emergency cesarean section at
the 34th gestational week because of decreasing fetal
movements during the last three days and non-reactive
cardiotocogram on admission. The newborn presented
with extreme pallor, blueberry muffin spots on the trunk
and face, respiratory distress, tachycardia and mild
hepatosplenomegaly. Laboratory testing demonstrated
severe and isolated hypoproliferative anemia (hemoglo-
bin: 33 g/L; reticulocyte count: 9.6=109/L, nucleated red
blood cell per 100 white blood cells: 2), a metabolic aci-
dosis with a lactate level of 7.6 mmol/L and a moderately
increased bilirubin (46 mmol/L). A first transfusion of red
blood cell (O Rh negative, non-cross matched) was
immediately administered (20 mL/kg). The baby’s con-
dition improved rapidly and the skin lesions disappeared
in the next 12 h. Abdominal ultrasound only revealed
mild hepatomegaly without ascites. Echocardiography
showed good left ventricular function without morpho-
logical anomaly. The direct antiglobulin test (DAT) was
positive (IgG) on cord blood cells. Both mother and child
were O Rh positive. Eluate from the newborn red blood
cells was not performed before the first transfusion and
DAT became negative thereafter. Indirect antiglobulin test
(IAT) of maternal serum was negative with panel cells, but
was clearly positive (3q) with the father’s red blood cells,
suggesting that a low incidence antigen (LIA) was
involved as the cause of immunization. Blood samples of
the mother as well as of the father were tested at the
reference laboratory of the Blood Transfusion Service
(Bern, Switzerland). Anti-Vw (anti-MNS9) was identified in
the serum of the mother. The father was MNS:-1,2,3,4,9
(Vw positive). Extensive investigations for infectious dis-
eases (Epstein Barr virus, cytomegalovirus, parvovirus
B19, toxoplasmosis, rubella, syphilis, enterovirus) were
not contributive. The Kleihauer-Betke test in the mother
was negative. A screening for pyruvate kinase and
glucose-6-phosphate dehydrogenase deficiency was
performed, and yielded normal results. Therefore, the
diagnosis of HDFN related to a LIA was confirmed.
Because of ongoing hemolysis with increasing levels
of total bilirubin (278 mmol/L on day 4), phototherapy was
performed until day 11. A second transfusion (20 mL/kg)
performed at day 2 was sufficient to bring the hemoglo-
bin level up to 140 g/L. Four weeks later, the baby was
again transfused because of hemoglobin level of 75 g/L
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with a recticulocyte count of 40=109/L. The baby was
discharged thereafter. On the last follow-up at 10 weeks,
he was healthy and well growing, and showed no evi-
dence of neurological impairment. Hemoglobin was
112 g/L. The parents were informed of the risk in case
of future pregnancies.
Vw (Verweyst) belongs to the MNS blood group system
and is secondary to a gene conversion between genes
encoding for glycophorin A and glycophorin B (hybrid A-
B-A). The insert encoding the Vw gene results in an
amino acid polymorphism at position 28 (Threonine™
Methionine) leading to the loss of N-glycosylation of the
adjoining asparagine at position 26. It is a LIA but its
prevalence has been reported to be as high as 1.43% in
southeastern Switzerland w7x. This antibody has been
associated with severe HDFN w5, 7x. As expected, in all
reported cases, prenatal IAT were negative and, since
pregnancies were clinically uncomplicated, diagnosis
was only made at birth. Newborns were treated with
exchange transfusion and/or transfusion and intensive
phototherapy. Retrospectively, some older asymptomatic
siblings were also tested Vw positive. In our case,
HDFN occurred already in the second pregnancy after a
probable immunization during the first pregnancy
(termination).
This case report highlights two different aspects that
are severe anemia of the newborn despite negative
screening tests and apparent suppression of hemato-
poiesis due to alloantibodies. Alloantibodies against LIA
are of little concern in pretransfusion testing, because the
risk for a patient to receive incompatible red cell units
remains very low. In practice, the screening red blood
cells used in antenatal testing are identical to those used
in pretransfusion testing. According to the recommen-
dations of the Swiss Transfusion Service, the panel cells
that are used must include antigens with a frequency of
more than 8% of the Caucasian population. Thus, it is
important to remember that routine IAT testing ignores
most antibodies that are specific for LIA and missing
such antibodies may be of great concern in some cases,
taking into account that the probability of fetal inheri-
tance of the incompatible antigen can be as high as
100%, if the father carries the antigen. Therefore, if the
antibody screen is negative but alloimmune hemolytic
disease is still suspected, testing of the father’s red blood
cells with the maternal serum is of great interest because
reagents for rare antigen are not available in all labora-
tories. In presence of ABO incompatibility between the
mother and the father, the absorption of anti-A and anti-
B should be performed.
The present case is also relevant because hemolysis
was associated with severe reticulocytopenia and
absence of erythroblastosis at birth, and was quite pro-
longed, therefore a transfusion was still necessary at day
27 of life. A similar observation was reported in the lit-
erature (absence of significant reticulocytosis and late
transfusion requirement) w5x. These findings suggest that
a suppression of erythropoiesis at the progenitor-cell
level by anti-Vw, exacerbating anemia, may be involved
in such cases. Inhibition of erythroid progenitors has
already been demonstrated in vitro for anti-Kell sensiti-
zation w8, 9x, and more recently for anti-Gerbich 3, an
antigen of glycophorin C and D w1, 3x. Glycophorin A
appears to be present early in maturation stage of red
cells (before RhD but after Kell antigens), as demonstrat-
ed with assays on erythroid cultures w2x. Nevertheless,
pathogenicity of anti-Vw remains unknown and this
hypothesis requires further in vitro investigations. Gly-
cophorin contributes to most of the carbohydrates on the
red blood cell membrane, which have abundant sialic
acid, and confers negative charge, but nothing is known
about a putative role in erythroid differentiation or growth.
In this case, the diagnosis of HDFN was only sus-
pected after birth because the DAT was positive. DAT is
known to have a limited usefulness to screen HDFN. A
retrospective study of 1724 DAT analyzed on unselected
umbilical cord blood samples showed a positive predic-
tive value of 23% and a sensitivity of 86% for the sub-
sequent development of hyperbilirubinemia w4x. However,
the significance of a positive DAT should not be neglect-
ed in the presence of non-regenerative anemia of the
newborn, even if IAT of maternal serum is negative.
This case confirms that anti-Vw may be responsible for
severe HDFN, which is certainly always missed during
routine screening, and may be associated with suppres-
sion of erythropoiesis. Unfortunately, no cost-effective
routine prenatal testing can be offered to prevent such a
complication. However, we should keep in mind, that if
fetal anemia is suspected, crossmatch of the paternal red
blood cell with the maternal serum can help to rule out
or confirm alloimmunization.
In case of subsequent pregnancies (or of a similar sit-
uation in another patient), the following recommenda-
tions can be proposed. We strongly favor regular
scanning of the middle cerebral artery peak velocity to
detect fetal anemia early in pregnancy and to propose
intrauterine fetal transfusions, if necessary. Prenatal phe-
notyping or genotyping w7x would be of great interest,
since homozygous individuals are exceptional. However,
the risk of complications of an invasive procedure should
be carefully taken into consideration. Finally, PCR analy-
sis of free fetal DNA in maternal blood samples should
be discussed, taking into account the fact that this test
has not been validated for ‘‘routine’’ MNS polymorphism
evaluation. Titration of anti-Verweyst antibodies with
paternal red cells is also possible but is not recommend-
ed because of its potentially poor predictive value, as in
anti-K titration.
In conclusion, this case confirms the clinical and bio-
logical heterogeneity of HDFN, and highlights the limits
of routine prenatal IAT. The question is whether the
increasing use of Doppler ultrasound to detect fetal ane-
mia will diminish the number of late diagnoses.
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